Veterinary-grade sulfaguanidine (SG, Sulfamidine), CAS 57-67-2, is the 4-amino-N-(diaminomethylidene)benzenesulfonamide base supplied as an active pharmaceutical ingredient for downstream dosage-form manufacture. The molecular formula C₇H₁₀N₄O₂S corresponds to a relative molecular mass of 214.24 g/mol. The substance is a white to almost white crystalline powder with low aqueous solubility; the melting point is reported with decomposition, and the definitive acceptance interval should be taken from the applicable pharmacopoeial monograph. Identification is confirmed by infrared absorption spectrophotometry (Ph. Eur. 2.2.24) against a qualified reference standard. The API is intended for formulation into tablets, capsules, powders, granules, premixes, oral solutions, and suspensions. Injection-grade applications require additional specification controls because the free base has limited solubility in neutral aqueous vehicles.

Assay by liquid chromatography (Ph. Eur. 2.2.29; USP <621>) is typically controlled at 98.5–101.0% on the dried basis for veterinary-grade material. Related substances are controlled by area normalization: total impurities not more than 0.5%, unspecified impurities not more than 0.10%. Loss on drying at 105°C for 2 h (Ph. Eur. 2.2.32; USP <731>) is not more than 0.5%. Residue on ignition (USP <281>) is not more than 0.1%. Elemental impurities are controlled according to ICH Q3D; class 1 metals such as lead, arsenic, cadmium, and mercury should not exceed the monograph limits. Microbiological quality for non-sterile oral and premix grades should conform to Ph. Eur. 2.6.12 and 2.6.13: total aerobic microbial count not more than 1000 CFU/g, total combined yeasts and moulds not more than 100 CFU/g, and absence of Escherichia coli in 1 g. For injection-grade material, bacterial endotoxin testing by Ph. Eur. 2.6.14 or USP <85> should be applied, with the limit derived from the maximum intended dose and route; published data for this specific configuration is limited because sulfaguanidine is not a first-line injectable sulfonamide.

What Limits the Use of Sulfaguanidine Free Base in Aqueous Injection Preparations?

Solution dosage forms require ionized species. Sulfaguanidine is more soluble in dilute mineral acids because the guanidine and aniline functions protonate at low pH, but prolonged exposure below pH 3.0 can promote acid-catalyzed hydrolysis of the sulfonamide linkage during terminal sterilization. Neutral phosphate-buffered vehicles at pH 7.0–7.4 cannot reliably achieve concentrations above approximately 1 mg/mL at 25°C; therefore, injection-grade formulations are typically suspensions rather than true solutions. Terminal steam sterilization at 121°C for 15 min requires stability-indicating HPLC because sulfaguanidine can degrade to sulfanilic acid and guanidine under prolonged heat. When a clear injectable is required, the API is first dissolved in an acidified vehicle or a co-solvent system such as propylene glycol or glycofurol, then sterile-filtered through a 0.22 µm membrane; the free base must be completely dissolved before filtration. Co-solvent addition alters osmolality and injection-site tolerance, so the finished injectable should be adjusted to an osmolality of 285–310 mOsm/kg and a pH of 7.0–8.5 for intramuscular administration, unless regional prescribing guidance states otherwise. Published data for this specific configuration is limited because the compound is primarily used for non-systemic enteric indications.

Powder Flow, Granulation Boundaries, and Equipment Safety Margins

Wet granulation is the preferred manufacturing route for sulfaguanidine tablets and granules because the untreated API exhibits poor flow and high dusting tendency in direct compression. In a high-shear mixer, the dry blend is mixed at an impeller tip speed of 3–6 m/s and a chopper speed of 800–1500 rpm, with water or an aqueous binder solution added at 2–5% w/w of dry granulate mass. Over-wetting beyond 6% w/w produces hard agglomerates that resist milling and can prolong tablet disintegration beyond Ph. Eur. 2.9.1 acceptance limits. The wet mass is dried in a fluid-bed dryer with inlet air at 55–65°C to a final moisture content of 1.5–2.5% w/w, then milled through a 0.8–1.0 mm screen. For direct compression, particle size reduction to a d₉₀ below 150 µm improves content uniformity but can reduce flow and increase electrostatic charging during encapsulation. A glidant such as colloidal silicon dioxide at 0.5–1.0% w/w and a lubricant such as magnesium stearate at 0.25–0.75% w/w are commonly added; magnesium stearate should be blended for no more than 5 min because prolonged shear can reduce tablet tensile strength.

Tablet compression on a rotary press is typically performed at 5–15 kN for flat-faced punches; higher forces may cause capping because the powder bed undergoes elastic recovery. In-process controls include tablet hardness, friability per USP <1216> with a limit of not more than 1.0%, and disintegration per Ph. Eur. 2.9.1 or USP <701>. Blend uniformity is verified by sampling 10 locations and analyzing by HPLC with a relative standard deviation of not more than 5.0% for tablets, capsules, and premix intermediates.

Batch-to-batch variance in sulfaguanidine particle size can shift the granulation endpoint by 2–3% absolute water addition. When incoming API has a d₅₀ below 20 µm, the same binder level produces more fines and longer disintegration times; when d₅₀ exceeds 80 µm, content uniformity may fail in low-dose tablets. High-shear mills should be monitored because local temperature increases above 40°C can cause static charging and adherence to stainless steel surfaces. If discharge chutes are not grounded, powder bridging becomes more frequent at relative humidity below 30% RH.

For oral powders and granules, the API is geometrically diluted with lactose monohydrate, dextrose monohydrate, or starch in a ribbon blender. The carrier selection should account for moisture uptake: lactose monohydrate is preferred when storage humidity is below 60% RH, whereas dextrose monohydrate may require pre-drying at RH above 60% to prevent caking. Final sieve fraction is typically controlled between 0.150 mm and 1.000 mm for granules; powders intended for reconstitution are milled to pass through a 0.250 mm sieve. Oral solutions and drinking-water formulations require pH adjustment with citric acid or dilute hydrochloric acid to pH 3.5–5.0 to maintain solubility. Precipitation can occur in hard water containing calcium and magnesium ions; therefore chelating or buffering agents should be evaluated for compatibility. Light protection is required because sulfonamides are susceptible to photolytic discoloration.

Stability-Indicating Method Requirements for Forced Degradation Studies

The HPLC assay used for release and stability should be validated per ICH Q2(R1) and should separate sulfaguanidine from sulfanilic acid, guanidine, and related sulfonamide impurities. Forced degradation is conducted under acidic, alkaline, oxidative, thermal, and photolytic conditions; mass balance should be within 95–105% unless degradation products do not retain at the selected wavelength. The mobile phase usually consists of phosphate buffer at pH 3.0–3.5 and methanol or acetonitrile, with detection at 254 nm. Because the primary aromatic amine is readily photo-oxidized, solution and suspension samples must be protected from ultraviolet light during preparation. Dissolution testing for tablets is performed per USP <711>; a common quality-control medium is 0.1 M hydrochloric acid at 37°C with paddle speed 50 rpm. If dissolution exceeds 85% in 15 min, the product is considered rapidly dissolving, but slower profiles require a validated sampling schedule and discrimination against manufacturing variables.

When Sulfaguanidine Replaces Sulfadiazine or Sulfamethazine in Enteric Therapy

In veterinary practice, sulfaguanidine is distinguished from systemic sulfonamides by its limited gastrointestinal absorption. Sulfadiazine and sulfamethazine are absorbed across the intestinal epithelium to achieve therapeutic plasma concentrations, whereas sulfaguanidine remains largely within the intestinal lumen, producing high local drug concentrations. This residence behavior supports its historical use in bacterial enteritis and dysentery, but it also limits efficacy against systemic infections. The guanidine substituent increases molecular polarity and reduces passive membrane permeability relative to the N-heterocyclic sulfonamides. Resistance mechanisms—including plasmid-mediated sulfonamide resistance and altered dihydropteroate synthase binding—apply across the class; therefore sulfaguanidine should not be considered interchangeable with potentiated sulfonamides containing trimethoprim or ormetoprim. Compared with sulfaquinoxaline, which is used in coccidiosis programs, sulfaguanidine has a narrower enteric bacterial spectrum and should be selected only when local sensitivity data support use.

Dose selection follows regional veterinary prescribing information and species-specific formularies. Because the compound is poorly absorbed, systemic exposure is low, but residues remain a regulatory concern in food-producing animals; withdrawal periods must be assigned according to regional limits and residue depletion studies. Published data for this specific configuration is limited for some minor species, and extrapolation from published bovine or porcine kinetic data is not recommended without bioequivalence or tissue residue confirmation.

The API is incompatible with strong oxidizers and should not be dry-mixed with sodium nitrite or other nitrosating agents due to the possible formation of nitrosamine-like degradation products; this is a class-specific concern for sulfonamides containing a primary aromatic amine. Avoid combination with strongly alkaline fillers such as sodium carbonate, which can generate a hygroscopic sodium salt and accelerate moisture uptake. In premix operations, sequential addition with pre-mixtures containing calcium carbonate should be avoided because the alkaline surface can reduce dissolution of the free base in the gastrointestinal tract. For tablets and capsules, desiccants should be included if the package is exposed to tropical humidity cycles exceeding 75% RH at 40°C for more than 6 months; stability studies per ICH Q1A(R2) should be conducted at 25°C/60% RH and 40°C/75% RH to assign shelf life.